Conclusion
CML
Patients with resistant/intolerant CML-CP treated with asciminib in ASCEMBL showed a trend for improvement in CML disease- and treatment-related symptoms and HRQOL compared with baseline and relative to bosutinib within the first 48 weeks of treatment. Asciminib-treated patients did not report worsening of treatment-related symptoms, and asciminib treatment did not interfere with patients’ general life activities. These findings are consistent with 48-week clinical data, which support better safety and tolerability in the asciminib treatment arm [